Dechra gets FDA approval for generic entrant antibiotic
Source - SMW
Dechra Pharmaceuticals has received approval from the US Food and Drug Administration for a generic antibiotic.
The product is expected to be a first generic market entrant in a substantial antibiotic market; it is the first registration Dechra has achieved through Putney's development pipeline since it acquired the US-based business.
Dechra chief executive Ian Page said: "We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra's position in the US market."